Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Commentary|Videos|November 9, 2026
Oncology PulsePoint: What Updated CLL Guidelines Mean for Pharmacists
Author(s)Matthew Peery, PharmD, BCOP
In an interview with Pharmacy Times, Matthew Peery, PharmD, BCOP, discusses how updated chronic lymphocytic leukemia guidelines inform treatment selection and how pharmacists help patients manage adverse effects, navigate complex dosing schedules, and access medications.
Advertisement
Advertisement
In this Pharmacy Times PulsePoint interview, Matthew Peery, PharmD, BCOP, of VCU Health in Richmond, Virginia, discusses how updated chronic lymphocytic leukemia (CLL) guidelines can help clinicians choose among available regimens. He explains that the updated framework starts with whether a patient meets criteria for treatment, then considers fitness, comorbidities, and genetic findings such as del(17p) and TP53 mutations. Several options may still be appropriate for a given patient, and direct comparisons are unavailable for some regimens.
Related to this article
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
Advertisement
Advertisement